MORE►
clinical trial
Dr. Suchismita Acharya, co-founder and CEO of AyuVis [Photo: AyuVis]
Fort Worth’s AyuVis Receives $2.1M NIH Grant for Clinical Trial of New-Gen Immunotherapies
by Lance Murray | May 17, 2023
The grant from the National Heart, Lung, and Blood Institute will fund a first-in-human Phase 1 clinical trial of a new generation of immunotherapies. This is the fourth NIH grant AyuVis has received since its founding in 2014, doubling total non-dilutive funding to $4.2 million. Co-Founder and CEO Dr. Suchismita Acharya calls the move to a human trial "a huge milestone for AyuVis."
by David Kirkpatrick |
Mar 31, 2022
Fort Worth-based AyuVis just received its second patent in three months for its immunotherapy treatments that protect pre-term babies from a debilitating chronic lung disease that affects many pre-term infants on ventilators.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
MORE►
by Lance Murray |
Jan 8, 2020
The startup plans to use the funding to continue developing its technology and to position it as an innovator in ophthalmology. Eyevensys’ tech is a gene therapy platform to deliver ocular drugs via an electrotransfection system to the ciliary muscle of the eye.
MORE►
by Lance Murray |
May 20, 2019
The company said it will use the funding to expand its ongoing Phase 1 / 2 clinical trial and fund development programs.
MORE►
